Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02617 藥捷安康－Ｂ
TRANSTHERA-B
Listing Date2025/06/23    Listing in 3 Days
Listing Price13.150
Grey Market Performance
Last updated: 20/06/2025 19:59  Refresh
  • Bright Smart
    up 22.900 +9.750 (+74.144%)
    High
    23.000
     
    Low
    17.200
    Volume
    88,500
    One Lot Profit
    +4,875.00
  • Phillip
    up 22.200 +9.050 (+68.821%)
    High
    26.650
     
    Low
    13.000
    Volume
    1,430,000
    One Lot Profit
    +4,525.00
  • Futu
    up 22.250 +9.100 (+69.202%)
    High
    32.000
     
    Low
    16.020
    Volume
    1,751,000
    One Lot Profit
    +4,550.00
  • Bid
  • Ask
  • 22.550
  • (1) 500
  • 500 (1)
  • 23.100
  • 22.500
  • (1) 1K
  • 0 (0)
  • 23.150
  • 22.450
  • (0) 0
  • 0 (0)
  • 23.200
  • 22.400
  • (0) 0
  • 0 (0)
  • 23.250
  • 22.350
  • (0) 0
  • 0 (0)
  • 23.300
  • 22.300
  • (1) 1K
  • 0 (0)
  • 23.350
  • 22.250
  • (0) 0
  • 0 (0)
  • 23.400
  • 22.200
  • (0) 0
  • 0 (0)
  • 23.450
  • 22.150
  • (0) 0
  • 0 (0)
  • 23.500
  • 22.100
  • (1) 1K
  • 0 (0)
  • 23.550
  • Bid
  • Ask
  • 22.200
  • (5) 192K
  • 8K (7)
  • 22.300
  •  
  • (2) 6K
  • 7K (2)
  •  
  •  
  • (1) 5K
  • 6.5K (3)
  •  
  •  
  • (5) 2.5K
  • 4K (5)
  •  
  •  
  • (9) 13.5K
  • 4.5K (6)
  •  
 
Hide
COMPANY PROFILE

TransThera Sciences (Nanjing), Inc. is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The Group have discovered and developed one Core Product, built a pipeline of five clinical stage product candidates and one preclinical stage product candidate.

--

Tinengotinib (TT-00420), the Group’s Core Product, is an internally discovered and developed, registrational clinical stage, unique MTK inhibitor for the treatment of drug-resistant, relapsed or refractory cancers. Tinengotinib targets three key pathways including FGFR/VEGFR, JAK and Aurora.

--

As of June 4, 2025, the Group was undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China and the other as a multi-regional clinical trial involving the U.S..

--

The Group’s global partners comprise leading pharmaceutical companies, including LG Chem, Roche, Teijin, and EA Pharma. The Group derived revenue primarily from milestone payments from LG Chem in connection with the out-licensed TT-01025.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot500
GLOBAL OFFERING
No. of Offer Shares15.28M H shares
No. of International Offer Shares13.75M H shares
No. of HK Offer Shares1.53M H shares
Offer Price$13.15
Stock Code2617
Sponsor(s)CITIC Securities (Hong Kong) Limited, Huatai Financial Holdings (Hong Kong) Limited
Underwriter(s)CLSA Limited, Huatai Financial Holdings (Hong Kong) Limited, BOCOM International Securities Limited, BOCI Asia Limited, CMB International Capital Limited, SPDB International Capital Limited, TradeGo Markets Limited
TIME TABLE
Application PeriodJun 13 (Fri) - noon, Jun 18 (Wed)
Price Determination Date--
Result Announcement DateOn or before Jun 20 (Fri)
Result Announcement DateOn or before Jun 20 (Fri)
Result Announcement DateOn or before Jun 23 (Mon)
Dealings in Shares commence onJun 23, 2025. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$13.15
Capitalization5.22B
NAV / share ($)$1.9 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 13.15, the net proceeds raised would be HKD 161.30M, of which
90% : fund the research and development of Core Product Tinengotinib
10% : Working capital
IPO NEWS
20/06/2025 18:35
{New Stock}TRANSTHERA-B(02617) ends up 68.82% on grey market
20/06/2025 16:20
{New Stock}TRANSTHERA-B up 59.7% at HK$21 on grey market
Related Document
Prospectus Prospectus  Chinese VersionProspectus  English Version
Remark： The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
 :
Subscribing Lot :
Subscribing Fee :
Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2025 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.